Table 4.
Hypoglycaemia rates and events from baseline to 24 months for those remaining on the chosen treatment (%)
| Met/Incr | Met/SU | OR (95% CI)*vs. Met/Incr | Insulin ± any OAD | OR (95% CI)* vs. Met/Incr | |
|---|---|---|---|---|---|
| (n = 421) | (n = 154) | (n = 151) | |||
| Hypoglycaemia with need for help | 0.8 | 0.6 | 1.32 (0.12–15.0) | 1.4 | 2.42 (0.30–19.3) |
| Symptomatic hypoglycaemia without need for help | 4.3 | 10.3 | 3.13 (1.46–6.69) | 31.3 | 11.45 (5.90–22.2) |
| Asymptomatic hypoglycaemia without need for help | 3.6 | 10.1 | 2.74 (1.33–8.70) | 22.9 | 8.33 (4.33–16.0) |
| Any hypoglycaemia | 6.5 | 15.4 | 2.70 (1.48–4.92) | 37.1 | 8.35 (4.84–14.4) |
| Death | 1.7 | 3.2 | 2.11 (0.65–6.87) | 7.3 | 4.65 (1.68–12.9) |
| Combined endpoints | |||||
| MACCE | 2.6 | 5.8 | 2.31 (0.93–5.78) | 8.0 | 3.08 (1.27–7.48) |
| Macrovascular complications | 1.7 | 2.7 | 1.53 (0.43–5.44) | 2.1 | 1.04 (0.25–4.42) |
| Microvascular complications† | 7.7 | 6.0 | 0.87 (0.40–1.90) | 20.7 | 3.84 (2.13–6.90) |
Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; MACCE, major cardiac or cerebrovascular event. †Excluding those with any neuropathy and any retinopathy at baseline. *Adjusted for differences in baseline characteristics: age, sex, diabetes duration, and coronary artery disease.